Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.
Fabry disease is an X-linked disorder of glycosphingolipid metabolism that results in progressive accumulation of neutral glycosphingolipids, (predominately globotriaosylceramide; GL-3) in lysosomes, as well as other cellular compartments and the extracellular space. Our aim was to characterize the...
Guardado en:
Autores principales: | Aurelie Nguyen Dinh Cat, Brigitte Escoubet, Vincent Agrapart, Violaine Griol-Charhbili, Trenton Schoeb, Wenguang Feng, Edgar Jaimes, David G Warnock, Frederic Jaisser |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bea0ae7dd6704052befae85e8921d938 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling.
por: Smail Messaoudi, et al.
Publicado: (2012) -
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fernando C Fervenza, et al.
Publicado: (2008) -
A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.
por: Andreas D Kistler, et al.
Publicado: (2011) -
Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy
por: Marian Goicoechea, et al.
Publicado: (2021) -
First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland [version 2; peer review: 2 approved]
por: Michał Nowicki, et al.
Publicado: (2021)